VK-2019

• Description :

  VK-2019 is an oral active, selective EBNA1 ((Epstein-Barr Nuclear Antigen 1) inhibitor and can be used for study of EBV-associated carcinomas[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  EBV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/vk-2019.html

• Purity :

  99.97

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(C1=C(C2=CC3=C(C=CN3)C=C2)C(C#CC4=CC=C(COC5CCOCC5)C=C4)=CC=C1)O

• Molecular Formula :

  C29H25NO4

• Molecular Weight :

  451.51

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Davis MT, et al. Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of VK-2019, a selective EBNA1 inhibitor. Biomed Chromatogr. 2024;38 (2) :e5775.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• CAS Number :

  [2044520-06-9]